Obesity is a medical condition, plain and simple
1 However, scientists are still investigating the other effects of GLP-1 on the brain
Phase 3 MASLD master protocol (NCT07165028, see Retatrutide and fatty liver): multi-agent MASLD program that includes retatrutide not a dedicated retatrutide-only liver trial
Try it, share it with someone who hates missing out on dessert, and let me know how it changes your snack game
Retatrutide carries a unique side effect, dysesthesia (tingling or burning sensations), reported in roughly 20.9% of participants at the 12 mg dose, not observed with tirzepatide [3]
Mild redness or tenderness at the injection site, slight headache, or brief lightheadedness all typically minimal and short-lived